MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-γ

Molecular Immunology

Volumn 44, Issue 11, 2007, Pages 2923-2932

  Zhao, Mojun ^a   Flynt, Frederick L ^a   Hong, Mei ^a   Chen, Han ^a   Gilbert, Carolyn A ^a   Briley, Nicole T ^a   Bolick, Sophia C ^b   Wright, Kenneth L ^b   Piskurich, Janet F ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Blimp 1; CIITA; IFN ; IFN R1; IRF 1; IRF 2; Myeloma; PRDI BF1; STAT1

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POSITIVE REGULATORY DOMAIN 1 BINDING FACTOR 1; STAT1 PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; BINDING SITE; CELL NUCLEUS; CONTROLLED STUDY; DNA BINDING; DNA STRUCTURE; E BOX ELEMENT; GAS GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; UPREGULATION; WESTERN BLOTTING;

B-LYMPHOCYTES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; MULTIPLE MYELOMA; NUCLEAR PROTEINS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTORS, INTERFERON; REPRESSOR PROTEINS; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 33947142391     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.01.009     Document Type: Article

References (51)

1. Altun M., Galardy P.J., Shringarpure R., Hideshima T., LeBlanc R., Anderson K.C., Ploegh H.L., and Kessler B.M. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 65 (2005) 7896-7901
2. Amiot L., Onno M., Lamy T., Dauriac C., Le Prise P.Y., Fauchet R., and Drenou B. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br. J. Haematol. 100 (1998) 655-663
3. Beatty G.L., and Paterson Y. Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol. Res. 24 (2001) 201-210
4. Cha Y., and Deisseroth A.B. Human interferon regulatory factor 2 gene: intron-exon organization and functional analysis of 5′-flanking region. J. Biol. Chem. 269 (2004) 5279-5287
5. Chen H., Gilbert C.A., Hudson J.A., Bolick S.C., Wright K.L., and Piskurich J.F. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Mol. Immunol. 44 (2007) 1461-1470
6. Chim C.S., Fung T.K., Cheung W.C., Liang R., and Kwong Y.L. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103 (2004) 4630-4635
7. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12 (1994) 259-293
8. Dong Y., Rohn W.M., and Benveniste E.N. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes. J. Immunol. 162 (1999) 4731-4739
9. Fuji H., and Iribe H. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Cancer Res. 46 (1986) 5541-5547
10. Galea H.R., Denizot Y., and Cogne M. Light chain myeloma plasma cells induce a strong cell-mediated immune response mainly directed against the monoclonal light chain determinants in a murine experimental model. Cancer Immunol. Immunother. 51 (2002) 229-234
11. Ghosh N., Gyory I., Wright G., Wood J., and Wright K.L. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem. 276 (2001) 15264-15268
12. Gyory I., Fejer G., Ghosh N., Seto E., and Wright K.L. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J. Immunol. 170 (2003) 3125-3133
13. Harada H., Takahashi E., Itoh S., Harada K., Hori T.A., and Taniguchi T. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol. Cell Biol. 14 (1994) 1500-1509
14. Harton J.A., and Ting J.P. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol. Cell Biol. 20 (2000) 6185-6194
15. Holling T.M., Schooten E., Langerak A.W., and van den Elsen P.J. Regulation of MHC class II expression in human T-cell malignancies. Blood 103 (2004) 1438-1444
16. Klein B., Zhang X.G., Lu Z.Y., and Bataille R. Interleukin-6 in human multiple myeloma. Blood 85 (1995) 863-872
17. Kotenko S.V., and Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19 (2000) 2557-2565
18. Kuo T.C., and Calame K.L. B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J. Immunol. 173 (2004) 5556-5563
19. Landmann S., Muhlethaler-Mottet A., Bernasconi L., Suter T., Waldburger J.M., Masternak K., Arrighi J.F., Hauser C., Fontana A., and Reith W. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J. Exp. Med. 194 (2001) 379-391
20. Leibundgut-Landmann S., Waldburger J.M., Krawczyk M., Otten L.A., Suter T., Fontana A., Acha-Orbea H., and Reith W. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 34 (2004) 1513-1525
21. Lin Y., Wong K., and Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 276 (1997) 596-599
22. Morimoto Y., Toyota M., Satoh A., Murai M., Mita H., Suzuki H., Takamura Y., Ikeda H., Ishida T., Sato N., Tokino T., and Imai K. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br. J. Cancer 90 (2004) 844-852
23. Morris A.C., Beresford G.W., Mooney M.R., and Boss J.M. Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol. Cell Biol. 22 (2002) 4781-4791
24. Muhlethaler-Mottet A., Di B.W., Otten L.A., and Mach B. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8 (1998) 157-166
25. Muhlethaler-Mottet A., Otten L.A., Steimle V., and Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16 (1997) 2851-2860
26. Nagabhushanam V., Solache A., Ting L.M., Escaron C.J., Zhang J.Y., and Ernst J.D. Innate inhibition of adaptive immunity: mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J. Immunol. 171 (2003) 4750-4757
27. Nagy M., Chapuis B., and Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br. J. Haematol. 116 (2002) 429-435
28. Pai R.K., Askew D., Boom W.H., and Harding C.V. Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J. Immunol. 169 (2002) 1326-1333
29. Pine R., Decker T., Kessler D.S., Levy D.E., and Darnell Jr. J.E. Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either. Mol. Cell Biol. 10 (1990) 2448-2457
30. Piskurich J.F., Gilbert C.A., Ashley B.D., Zhao M., Chen H., Wu J., Bolick S.C., and Wright K.L. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma. Mol. Immunol. 43 (2006) 519-528
31. Piskurich J.F., Lin K.I., Lin Y., Wang Y., Ting J.P., and Calame K. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol. 1 (2000) 526-532
32. Piskurich J.F., Linhoff M.W., Wang Y., and Ting J.P. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol. Cell Biol. 19 (1999) 431-440
33. Piskurich J.F., Wang Y., Linhoff M.W., White L.C., and Ting J.P. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene. J. Immunol. 160 (1998) 233-240
34. Portier M., Zhang X.G., Caron E., Lu Z.Y., Bataille R., and Klein B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 81 (1993) 3076-3082
35. Schaar C.G., Kluin-Nelemans H.C., Te Marvelde C., le Cessie S., Breed W.P., Fibbe W.E., van Deijk W.A., Fickers M.M., Roozendaal K.J., and Wijermans P.W. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann. Oncol. 16 (2005) 634-639
36. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75 (2004) 163-189
37. Shaffer A.L., Lin K.I., Kuo T.C., Yu X., Hurt E.M., Rosenwald A., Giltnane J.M., Yang L., Zhao H., Calame K., and Staudt L.M. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17 (2002) 51-62
38. Shapiro-Shelef M., and Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol. 5 (2005) 230-242
39. Shi B., Vinyals A., Alia P., Broceno C., Chen F., Adrover M., Gelpi C., Price J.E., and Fabra A. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription. Implication of CIITA in tumor and metastasis development. Int. J. Biochem. Cell Biol. 38 (2006) 544-562
40. Takahashi N., Mundy G.R., and Roodman G.D. Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J. Immunol. 137 (1986) 3544-3549
41. Ting J.P., and Trowsdale J. Genetic control of MHC class II expression. Cell 109 (2002) S21-S33
42. Tooze R.M., Stephenson S., and Doody G.M. Repression of IFN-gamma induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling. J. Immunol. 177 (2006) 4584-4593
43. Treon S.P., Pilarski L.M., Belch A.R., Kelliher A., Preffer F.I., Shima Y., Mitsiades C.S., Mitsiades N.S., Szczepek A.J., Ellman L., Harmon D., Grossbard M.L., and Anderson K.C. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J. Immunother. 25 (2002) 72-81
44. Turner Jr. C.A., Mack D.H., and Davis M.M. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77 (1994) 297-306
45. van den Elsen P.J., Holling T.M., van der Stoep N., and Boss J.M. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin. Immunol. 109 (2003) 46-52
46. Wen Y.J., Barlogie B., and Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97 (2001) 1750-1755
47. Wong L.H., Sim H., Chatterjee-Kishore M., Hatzinisiriou I., Devenish R.J., Stark G., and Ralph S.J. Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. J. Biol. Chem. 277 (2002) 19408-19417
48. Wu C., Sun M., Liu L., and Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306 (2003) 1-12
49. Xi H., and Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Mol. Immunol. 39 (2003) 677-684
50. Xi H., Eason D.D., Ghosh D., Dovhey S., Wright K.L., and Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene 18 (1999) 5889-5903
51. Yi Q., Dabadghao S., Osterborg A., Bergenbrant S., and Holm G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 90 (1997) 1960-1967